Figure 2. Targeted inhibition of irreversible EGFR-TKI-sensitive H1975 lung adenocarcinoma cells also results in “early' emergence of tumor resistant escape survivor cells with activated prosurvival-antiapoptotic signaling.
A, Significant resistant shift of cell viability in H1975 cells that survived 9 days of CL-387,785 treatment. B, Activation of p-STAT3[Y705]/BCL-2/BCL-XL signaling in H1975 cells that survived 9 days of CL-387,785 treatment. C, Reactivated p-EGFR and downstream signaling in Day 9-resistant-survivors H1975 cells against CL-387,785 (1μM) could be inhibited by higher dose of CL-387,785 (5μM) in retreatment, but not p-STAT3 or BCL-2.